eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

3/2015
vol. 7
 
Share:
Share:
more
 
 
abstract:

Case reports
High-dose-rate brachytherapy – a novel treatment approach for primary clear cell adenocarcinoma of male urethra

Shirley Lewis, Mahendra Pal, Ganesh Bakshi, Yogesh G. Ghadi, Santosh Menon, Vedang Murthy, Umesh Mahantshetty

J Contemp Brachytherapy 2015; 7, 3: 248-251
Online publish date: 2015/06/15
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 

The incidence of male urethral cancer is rare with age preponderance of 50 to 60 years. The standard management approach is surgery. Here, we present a novel treatment approach for male urethral cancer. Thirty-six year old male, case of primary clear cell adenocarcinoma of urethra who refused surgery, underwent cystoscopic assisted intraluminal HDR brachytherapy. Patient received a dose of 36 Gy in 9 fractions (4 Gy per fraction) followed by a boost of 24 Gy in 6 fractions. At 11 months post treatment, disease is well controlled with no post treatment toxicity so far. Intraluminal brachytherapy seems to be an effective novel treatment for male urethral cancer.
keywords:

adenocarcinoma, HDR brachytherapy, intraluminal brachytherapy, urethral cancer

 
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe